Jointly Funded Research Explores Cutting-Edge RNA Sequencing in Rare Ovarian Cancer
STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Fund Breakthrough Research at MD Anderson Cancer Center to Advance Low-Grade Ovarian Cancer Treatment
HOUSTON, TEXAS / ACCESS Newswire / April 30, 2025 / Two patient-driven ovarian cancer nonprofits - STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries - have awarded a $115,580 research grant to Dr. Kwong-Kwok Wong at The University of Texas MD Anderson Cancer Center to investigate new biomarkers that could improve treatment options for patients with low-grade serous ovarian cancer (LGSOC).MD Anderson Cancer Center MD Anderson Cancer Center in Houston, TX is where the ovarian cancer research project with Not These Ovaries is being funded.
The research study will utilize long-read RNA sequencing, a cutting-edge technology that allows scientists to examine full-length RNA transcripts in greater detail than previously possible. This technique could identify novel gene fusions and biomarkers that indicate whether a patient will respond to chemotherapy or endocrine therapy - an urgent need in LGSOC, where traditional treatments often show limited effectiveness.
'This pilot project is exploring a promising technology to perform more accurate measurements of transcript activities and discover new genetic markers in low-grade serous ovarian cancer,' said Dr. Wong, principal investigator at MD Anderson. 'As the accuracy of long-read sequencing improves, we are optimistic about the potential in clinical applications for patients who need better options.'
Currently, only 20% of LGSOC patients respond to platinum-based chemotherapy, the standard of care for other ovarian cancer types. Patients typically undergo surgery followed by chemotherapy and treatment with aromatase inhibitors, which block estrogen production. However, outcomes remain limited due to the unique biology of LGSOC and the lack of personalized therapies.
The study will analyze RNA samples from patients who have and have not responded to chemotherapy or hormone therapy, with the goal of uncovering molecular patterns that could guide treatment decisions and lead to more tailored, effective care.
'This research directly addresses the gap in options for patients with this rare and underfunded cancer,' said Emily Campbell, Executive Director of Not These Ovaries. 'We are proud to invest in innovative science that puts patients at the center of progress.'
'STAAR was founded by LGSOC survivors to drive critical research for a disease that has been overlooked for too long,' said Nicole Andrews, Chair of STAAR. 'We're excited to partner with Not These Ovaries and MD Anderson to accelerate discoveries that could change lives.'
About Not These Ovaries
Not These Ovaries is dedicated to quickly funding research and trials to eradicate ovarian cancer, with a focus on understudied and underfunded subtypes that primarily affect younger women. Its transparent model ensures 100% of donations fund immediate research and trials, while also empowering patients and families through education and actionable information.
https://www.nottheseovaries.org/
About STAAR Low-Grade Serous Ovarian Cancer Foundation
STAAR raises critical funds for life-saving research focused on low-grade serous ovarian cancer (LGSOC), a rare and often misunderstood subtype affecting fewer than 10% of ovarian cancer patients. Founded by LGSOC patients, STAAR drives innovation in diagnostics and treatments while collaborating with global research partners to advance care for this community.
https://www.staaroc.org/
Contact InformationEmily Campbell Executive Director (786) 814-1700
SOURCE: Not These Ovaries
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology VSTM shares rallied 22.2% in a month, primarily driven by the FDA approval of the company's novel combination regimen of avutometinib plus defactinib in early May for treating KRAS mutant recurrent low-grade serous ovarian cancer (LGSOC), a rare and distinct type of ovarian cancer. The FDA's decision came well in advance of the originally expected date of June 30, 2025. The approval was granted under the FDA's accelerated approval pathway and is commercialized in the U.S. market as an oral combination co-pack with the two prescription products, known as 'Avmapki Fakzynja Co-Pack.' Following the FDA approval, Avmapki Fakzynja Co-Pack is the first and only FDA-approved treatment for the LGSOC indication. Per Verastem Oncology, the combo offers a much-needed treatment option for patients and sets a new standard of care for women with recurrent LGSOC with a KRAS mutation. Full approval of the product for this use depends on the detailed evidence of clinical benefit in the follow-up phase III RAMP 301 confirmatory study, which will evaluate the combination in women with and without a KRAS mutation. Year to date, Verastem Oncology stock has surged 64.8% against the industry's 5.8% decline. Image Source: Zacks Investment Research Please note that the FDA's decision was based on the results from VSTM's phase II RAMP 201 study, which evaluated the combination of Avmapki and Fakzynja in adult patients with measurable KRAS-mutated recurrent LGSOC. Per the data readout, a 44% overall response rate was observed in patients treated with the combo therapy, with an acceptable safety profile. Additionally, the median duration of response ranged from 3.3 to 31.1 months in the KRAS mutant population. The Avmapki/Fakzynja combo enjoys the FDA's Breakthrough Therapy designation for the treatment of patients with recurrent LGSOC after one or more prior lines of therapy, including platinum-based chemotherapy, in the United States. Avutometinib alone or in combination with defactinib also enjoys the FDA's Orphan Drug designation for the same indication. Verastem Oncology is also looking to expand the label of its approved avutometinib/defactinib combo therapy beyond LGSOC. Last week, VSTM reported positive updated safety and efficacy results from the phase I/II RAMP 205 study evaluating avutometinib plus defactinib in combination with chemotherapy (gemcitabine and Nab-paclitaxel) for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) patients. This has also likely contributed to the stock price rally in the past month. The RAMP 205 study is evaluating 60 patients in five cohorts (12 per cohort) who are receiving one of five dose regimens of avutometinib/defactinib combo with chemotherapy for frontline metastatic PDAC. As of April 25, 2025, patients in the dose level 1 cohort achieved an overall response rate of 83% (eight confirmed and two unconfirmed who remain on treatment). Based on this encouraging outcome, Verastem Oncology selected dose level 1 as the recommended phase II dose. Additionally, it was found that the dose level 1 showed the best response, and overall, 92% of patients across all dose levels achieved tumor shrinkage. The safety profile of the avutometinib/defactinib combo was acceptable across all the treatment cohorts and no new safety signals were identified. Verastem Oncology is currently gearing up to initiate a registrational phase III front-line metastatic PDAC study in 2026. Apart from these indications, the company is simultaneously evaluating avutometinib and defactinib in combination with a KRAS G12C inhibitor, sotorasib, for treating non-small cell lung cancer in a separate mid-stage study. Verastem, Inc. price-consensus-chart | Verastem, Inc. Quote Verastem Oncology currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Bayer BAYRY, Lexicon Pharmaceuticals LXRX and Amarin AMRN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Bayer's earnings per share have increased from $1.19 to $1.25 for 2025. During the same time, earnings per share have increased from $1.28 to $1.31 for 2026. Year to date, shares of Bayer have gained 45.3%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. In the past 60 days, estimates for Lexicon's loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 6.6%. LXRX's earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%. In the past 60 days, estimates for Amarin's loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 17.1%. AMRN's earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Lexicon Pharmaceuticals, Inc. (LXRX) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Verastem, Inc. (VSTM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
Cuts at what cost? Childhood care and education leaders weigh in on spending bill's impacts
( — As the Senate continues to debate the passage of the 'Big, Beautiful Bill', California leaders in early childhood care and education are anticipating the impacts of looming federal cuts. Bianca Ventura sat down with First 5 California and Child Care Resource Center representatives on Wednesday. The two organizations have been advocating for California children and families on Capitol Hill. Though they've seen bipartisan support in preserving children's resources like Head Start, they say potential cuts to Medi-Cal and nutritional programs like SNAP could impact children's overall health. 'There are huge cuts proposed in the House reconciliation package to the Medicaid program,' said Vice President of the Child Care Resource Center, Donna Sneeringer. 'Many of those recipients are young children. I think one of the things that we have been trying to speak with lawmakers about, as well as with the public, is that this will not just impact those who are receiving those services through Covered California. They are going to impact our overall health care system. Particularly our rural health care system, our hospitals. It will impact our emergency room services. Everyone's care will become harder to come by and more expensive.' If federal investments are rolled back on health services, food support, and child care, the experts we spoke with anticipate that some of the costs will be shifted. Possibly putting the burden on employers to provide access to health care. 'A lot of businesses, because they are also struggling themselves with the affordability crisis and materials. They can't necessarily afford the robust health care that their employees deserve,' said First 5 California Executive Director, Jackie Wong. 'However, a lot of their employees are likely on Medicaid.' Wong adds that many of those employees work entry-level positions that the state relies on to support the economy. As for education, when we last checked in with leaders in early childhood development and care. President Trump's executive order to dismantle the Department of Education was still in effect. Since then, a federal judge blocked the administration's efforts to eliminate the department while ordering the rehiring of employees who were fired in mass layoffs. Yet, Wong tells us cuts within the department have made it difficult to carry out administrative tasks, like completing payments to Head Start providers. She even learned of cuts to certain programs the last time she traveled to Washington D.C. to speak with Congressional leaders. 'While we were there, actually, we had gotten wind that grants to steward mental health got cut,' said Wong. 'They are actually, in real time, pulling back and clawing back their investments that actually have supported young learners, as well as our students and our student community.' As for what's next? Representatives with First 5 California and the CCRC are going to continue their advocacy in Washington D.C. CCRC is currently collecting stories in hopes of sharing them with congressional lawmakers who want to hear the impacts of federal funding cuts firsthand. Families and caregivers are encouraged to share their testimonies of how they are making ends meet while navigating food costs, health and child care, along with living expenses. You can find more details and pass along your story to state representatives by visiting Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Bloomberg
4 days ago
- Bloomberg
Singapore Firms Eye Philippine Green Energy Projects, PM Wong Says
Singaporean companies are interested to invest in renewable energy projects in the Philippines, the city-state's Prime Minister Lawrence Wong said during a visit to Manila. 'We agreed on the importance of expanding our collaboration in renewable energy,' Wong said during a joint briefing with President Ferdinand Marcos Jr. after their bilateral meeting on Wednesday.
